ID   NML
AC   CVCL_WH38
DR   Wikidata; Q98127945
RX   PubMed=24035468;
RX   PubMed=27292541;
RX   PubMed=30268330;
CC   Sequence variation: Mutation; VGNC; VGNC:38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468).
CC   Derived from site: In situ; Nail bed; UBERON=UBERON_0005273.
DI   NCIt; C120298; Canine melanoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 19-12-24; Version: 8
//
RX   PubMed=24035468; DOI=10.1016/j.tvjl.2013.08.003;
RA   Ito K., Kobayashi M., Kuroki S., Sasaki Y., Iwata T., Mori K.,
RA   Kuroki T., Ozawa Y., Tetsuka M., Nakagawa T., Hiroi T., Yamamoto H.,
RA   Ono K., Washizu T., Bonkobara M.;
RT   "The proteasome inhibitor bortezomib inhibits the growth of canine
RT   malignant melanoma cells in vitro and in vivo.";
RL   Vet. J. 198:577-582(2013).
//
RX   PubMed=27292541; DOI=10.1111/jvp.12336;
RA   Kuroki S., Kobayashi M., Tani H., Miyamoto R., Kurita S., Tamura K.,
RA   Ono K., Washizu T., Bonkobara M.;
RT   "Selective growth inhibition by suppression of F1Fo ATPase in canine
RT   malignant melanoma cell lines.";
RL   J. Vet. Pharmacol. Ther. 40:101-104(2017).
//
RX   PubMed=30268330; DOI=10.1016/j.tvjl.2018.09.001;
RA   Miyamoto R., Kurita S., Tani H., Ikeda T., Ishizaka M., Saima H.,
RA   Kobayashi M., Tamura K., Bonkobara M.;
RT   "Canine squamous cell carcinoma cell lines with high expression of
RT   survivin are sensitive to survivin inhibitor YM155.";
RL   Vet. J. 240:31-36(2018).
//